A Study of RO4917523 in Patients With Treatment Resistant Depression



Status:Archived
Conditions:Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:June 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Exploratory Fixed Dose Randomized Double Blind Parallel-group Placebo-controlled Study of the Safety and of the Therapeutic Effects of Ro 4917523 in Patients With Treatment- Resistant Depression


This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison
to placebo, in patients with treatment-resistant depression. Following a washout period from
existing anti-depressant medication, cohorts of patients will be randomized to receive daily
oral RO4917523 at up to five different doses (according to the safety and tolerability
observed at the lower doses during the study), or placebo. The anticipated time on study
treatment is 10 days (in an inpatient unit), and the target sample size is <100 individuals.



We found this trial at
6
sites
Clinical Trial Facility
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Clinical Trial Facility
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Trial Facility
Jackson, Mississippi
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Clinical Trial Facility
Metairie, Louisiana
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Clinical Trial Facility
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Trial Facility
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials